News

Threefold increase in cirrhosis risk with HCV


 

References

Individuals with hepatitis C infection are three times more likely to develop cirrhosis than are those who are hepatitis C negative, and fibrosis progression is pronounced within the first 5 years after infection, a retrospective cohort study has found.

Analysis of 10-year follow-up data from 1,840 individuals in a national database of hepatitis C (HCV) infected veterans, and 1,840 uninfected controls, found 18.4% of HCV+ individuals developed cirrhosis, compared with 6.1% of uninfected individuals, and they had a significantly higher rate of hepatic decompensation events (1.79% vs. 0.33%).

Increasing age, white race, hypertension, anemia, and a history of alcohol abuse were associated with a higher risk of cirrhosis among HCV+ individuals, but baseline or recent history of alcohol abuse or dependence did not significantly impact risk, according to a paper published online in JAMA Internal Medicine (2015;175:178-85 [doi:10.1001/jamainternmed.2014.6502]).

Courtesy NIH

“Our study shows that fibrosis progression after HCV infection starts early and that a substantial proportion of HCV-infected persons develop significant fibrosis or cirrhosis within the first 5-10 years of infection [but] on the other hand, progression of cirrhosis to hepatic decompensation is uncommon in the first 9 years after cirrhosis,” wrote Dr. Adeel A. Butt of the University of Pittsburgh, and colleagues.

The National Institutes of Health and the VA Pittsburgh Healthcare System supported the study. Two authors declared receiving grants and fees from private industry.

Recommended Reading

Aramchol shows promise for NAFLD; resveratrol disappoints
MDedge Family Medicine
VIDEO: Hepatitis C burden could wallop Medicare
MDedge Family Medicine
Achieving sustained response key to successful HCV treatment
MDedge Family Medicine
VIDEO: Pediatric NAFLD worsens as kids age
MDedge Family Medicine
Preventing, treating HBV reactivation during immunosuppressive therapy
MDedge Family Medicine
Diet, exercise reduced portal hypertension in obese cirrhotic patients
MDedge Family Medicine
Sofosbuvir and ribavirin critical to preventing posttransplantation HCV recurrence
MDedge Family Medicine
Analysis: Push for expanded hepatitis C screening appears premature
MDedge Family Medicine
Aetna customers to receive discount on Gilead’s hepatitis C treatment
MDedge Family Medicine
Updated HIV, HCV, HBV blood product screening test approved
MDedge Family Medicine